Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 20 mg) |
| Drug Class | Sphingosine 1-phosphate receptor modulators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Summary
- Ponesimod (Ponvory) is a disease-modifying therapy indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
- A network meta-analysis study found that among newer therapies for relapsing multiple sclerosis (RMS), only ublituximod ranked among the three most efficacious treatments while ponesimod did not make it to this list.
- In terms of safety profile comparison with other high-efficacy DMTs such as natalizumab, fingolimod, alemtuzumab etc., ponesimod showed significant differences leading to discontinuation of study drug compared to alemtuzumab and placebo according to one systematic review.
- Another systematic review revealed no significant difference between individual high-efficacy DMTs including ponesimod in terms of upper respiratory tract infections, nasopharyngitis fatigue and nausea when compared with each other or placebo.
- The information was derived from 3 documents which were all Systematic Reviews / Meta-Analyses focusing on comparing efficacy and safety profiles amongst various Disease Modifying Therapies used for treating Multiple Sclerosis patients.
- According to another network meta-analysis conducted on sphingosine-1-phosphate receptors like Ponesimod used in MS treatment, Ozanimid had better acceptability than Ponesimid but Amiselimid was considered most effective based on reduction in annualized relapse rate amongst these drugs.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ponvory (ponesimod) Prescribing Information. | 2023 | Janssen Pharmaceuticals, Inc. Titusville, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. | 2023 | Journal of Comparative Effectiveness Research |
| Ponesimod for treating relapsing–remitting multiple sclerosis. | 2022 | NICE |
| Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis. | 2022 | Neurological Sciences |
| Australian public assessment report for Ponvory. | 2021 | Australian Government: Department of Health |
| Assessment report: Ponvory. | 2021 | EMA |
| Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. | 2021 | Neurological Sciences |